| Testolactone | hsa00240 | Pyrimidine metabolism | 4.29E-02 | 2 | P21589, P04183 | NT5E, TK1 | More | |
| Testolactone | hsa00480 | Glutathione metabolism | 3.29E-04 | 4 | Q9UJ14, Q16772, P09211, P30041 | GGTL3, GSTA3, GSTP1, PRDX6 | More | |
| Testolactone | hsa00513 | Various types of N-glycan biosynthesis | 4.96E-02 | 1 | Q9NR34 | MAN1C1 | More | |
| Testolactone | hsa00564 | Glycerophospholipid metabolism | 4.29E-02 | 2 | Q6P1A2, P23743 | MBOAT5, DGKA | More | |
| Testolactone | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.46E-03 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | |
| Testolactone | hsa00982 | Drug metabolism - cytochrome P450 | 1.06E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | |
| Testolactone | hsa00983 | Drug metabolism - other enzymes | 1.72E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | |
| Testolactone | hsa01100 | Metabolic pathways | 8.43E-03 | 11 | P35790, Q16772, P09211, Q9UJ14, P30041, P40926, Q7KZN9, P15121, Q9UHK6, Q86VZ5, Q9BQB6 | CHKA, GSTA3, GSTP1, GGTL3, PRDX6, MDH2, COX15, AKR1B1, AMACR, SGMS1, VKORC1 | More | |
| Testolactone | hsa01524 | Platinum drug resistance | 4.44E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | |
| Testolactone | hsa04015 | Rap1 signaling pathway | 3.07E-02 | 4 | P25116, Q8TEU7, P08514, P17252 | F2R, RAPGEF6, ITGA2B, PRKCA | More | |
| Testolactone | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
| Testolactone | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | |
| Testolactone | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
| Testolactone | hsa04611 | Platelet activation | 3.39E-02 | 3 | P25116, P08514, P07359 | F2R, ITGA2B, GP1BA | More | |
| Testolactone | hsa04650 | Natural killer cell mediated cytotoxicity | 2.94E-02 | 3 | P16298, P50591, Q02750 | PPP3CB, TNFSF10, MAP2K1 | More | |
| Testolactone | hsa04672 | Intestinal immune network for IgA production | 1.35E-02 | 2 | P29965, P13765 | CD40LG, HLA-DOB | More | |
| Testolactone | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
| Testolactone | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | |
| Testolactone | hsa04918 | Thyroid hormone synthesis | 3.16E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | |
| Testolactone | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | |
| Testolactone | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | |
| Testolactone | hsa05203 | Viral carcinogenesis | 4.62E-02 | 3 | Q12933, P42229, Q15283 | TRAF2, STAT5A, RASA2 | More | |
| Testolactone | hsa05204 | Chemical carcinogenesis | 5.46E-03 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | |
| Testolactone | hsa05205 | Proteoglycans in cancer | 4.46E-02 | 4 | Q12955, Q14247, P17252, P08962 | ANK3, CTTN, PRKCA, CD63 | More | |
| Testolactone | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | |
| Testolactone | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | |
| Testolactone | hsa05310 | Asthma | 1.35E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
| Testolactone | hsa05320 | Autoimmune thyroid disease | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
| Testolactone | hsa05330 | Allograft rejection | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
| Testolactone | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.82E-02 | 3 | P14923, P08514, Q9UJU2 | JUP, ITGA2B, LEF1 | More | |
| Testolactone | hsa05416 | Viral myocarditis | 4.29E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
